Antidepressants differ on the QT interval, but none raised early cardiac events

Design

Individual-participant-data network meta-regression of double-blind randomised trials, plus aggregate pairwise meta-analysis

Population

8,679 adults with major depression for QTc; 52,398 across 139 trials for cardiovascular events

Primary outcome

Change in QTc (Fridericia) over 8 weeks; early major adverse cardiovascular events

Effect

Escitalopram +8.7 ms (1.6–15.8), amitriptyline +5.3 ms (0.8–9.8); no excess cardiac events (risk difference 0.01%, −0.01% to 0.02%)

An individual-participant-data network meta-regression harmonised double-blind trials of ten antidepressants against placebo in adults with major depression, with QT interval change over the first eight weeks as the primary outcome. Escitalopram and amitriptyline were associated with the largest QTc increases; venlafaxine and vortioxetine with the smallest. The effect varied considerably between people, especially for escitalopram, fluoxetine and mirtazapine.

Separately, an aggregate analysis of 139 trials and more than 52,000 participants found no association between antidepressant use and early major adverse cardiovascular events or non-suicidal sudden death.

The practical reading is not to avoid antidepressants, but to match the drug to the individual's cardiac risk. In a patient with a borderline baseline QTc, low potassium, or other QT-prolonging drugs, the choice between agents matters; in most patients the early cardiac event risk is not raised. Modifiable factors — electrolytes, interacting drugs — are worth checking before and after starting.

• Escitalopram prolonged QTc by about 8.7 ms vs placebo (95% credibility interval 1.6–15.8) and amitriptyline by 5.3 ms (0.8–9.8).
• Venlafaxine and vortioxetine were among the least QT-prolonging of the ten drugs studied.
• Across 139 trials (52,398 participants) there was no excess of early major cardiovascular events or non-suicidal sudden death (risk difference 0.01%, 95% credibility interval −0.01% to 0.02%).
• In a patient with a long baseline QTc or low potassium, prefer a lower-QT agent and correct modifiable factors first.

Why it matters

It replaces a blanket worry about antidepressants and the heart with a drug-by-drug, patient-by-patient decision.

Don't overread it

The QT findings are short-term surrogate measures; the reassuring cardiac-event analysis was aggregate, not individual-level.

The statistics, in plain English

A credibility interval is the Bayesian equivalent of a confidence interval; escitalopram's lower bound sitting above zero means the QT increase is unlikely to be chance, but an 8.7 ms rise is modest for most hearts. The near-zero risk difference for cardiac events, with its interval hugging zero, is a reassuring null.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.